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Mitochondria in neurons, in addition to their primary role in
bioenergetics, also contribute to specialized functions, including
regulation of synaptic transmission, Ca2+ homeostasis, neuronal ex-
citability, and stress adaptation. However, the factors that influence
mitochondrial biogenesis and function in neurons remain poorly elu-
cidated. Here, we identify an important role for serotonin (5-HT) as a
regulator of mitochondrial biogenesis and function in rodent cortical
neurons, via a 5-HT2A receptor-mediated recruitment of the SIRT1–
PGC-1α axis, which is relevant to the neuroprotective action of
5-HT.We found that 5-HT increasedmitochondrial biogenesis, reflected
through enhanced mtDNA levels, mitotracker staining, and expres-
sion of mitochondrial components. This resulted in higher mitochon-
drial respiratory capacity, oxidative phosphorylation (OXPHOS)
efficiency, and a consequential increase in cellular ATP levels. Mech-
anistically, the effects of 5-HTwere mediated via the 5-HT2A receptor
and master modulators of mitochondrial biogenesis, SIRT1 and PGC-
1α. SIRT1 was required to mediate the effects of 5-HT on mitochon-
drial biogenesis and function in cortical neurons. In vivo studies
revealed that 5-HT2A receptor stimulation increased cortical mtDNA
and ATP levels in a SIRT1-dependent manner. Direct infusion of 5-HT
into the neocortex and chemogenetic activation of 5-HT neurons also
resulted in enhanced mitochondrial biogenesis and function in vivo.
In cortical neurons, 5-HT enhanced expression of antioxidant en-
zymes, decreased cellular reactive oxygen species, and exhibited neu-
roprotection against excitotoxic and oxidative stress, an effect that
required SIRT1. These findings identify 5-HT as an upstream regulator
of mitochondrial biogenesis and function in cortical neurons and
implicate themitochondrial effects of 5-HT in its neuroprotective action.
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Serotonin (5-HT), a phylogenetically ancient molecule, inaddition to its multifaceted neurotransmitter function, has
been hypothesized to retain “prenervous” roles, including tro-
phic and morphogen-like actions (1, 2). Through an influence on
neurite outgrowth, synaptogenesis, and synaptic plasticity, 5-HT
exerts potent effects on neuronal plasticity in the developing and
mature nervous system (1, 3). It also evokes trophic factor-like
effects on cell proliferation, survival, and differentiation (2).
Mitochondria are highly dynamic organelles that are vital not only
for their bioenergetic role and their influence on cell survival, but
also subserve specialized functions of regulating excitability, synaptic
transmission, buffering Ca2+ homeostasis, and modulating structural
and functional synaptic plasticity in the context of neurons (4).
Mitochondrial biogenesis and function in neurons are hypothesized
to promote cell viability and mediate effective stress adaptation (5).
The vital importance of mitochondria in the context of neurons (4,
5) underscores the importance of studying upstream pathways that
drive mitochondrial biogenesis and function in neurons.
Mitochondrial biogenesis and function require the coordinated
transcription of nuclear- and mitochondrial-encoded genes and are
mediated via transcriptional regulators that respond to extracellular
and mitochondrial cues (6, 7). Several reports indicate that the
NAD+-dependent deacetylase SIRT1 and peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) serve as
master regulators of mitochondrial biogenesis and function by
controlling gene expression (6, 8). While SIRT1 and PGC-1α are
implicated in neuronal bioenergetics and survival (8), the upstream
cues that recruit the SIRT1–PGC-1α axis in neurons remain rela-
tively unexplored. It has been reported that 5-HT increases axonal
transport of mitochondria in hippocampal neurons (9), and an in-
fluence of 5-HT1F receptor activation on mitochondrial biogenesis
in dopaminergic neurons has been recently demonstrated (10).
We hypothesized that 5-HT may exert a putative trophic-like
action by serving as an upstream regulator of mitochondrial
biogenesis in neurons. To test this hypothesis, we used both in
vitro cortical neuronal cultures and in vivo studies, employing
pharmacological and genetic perturbation strategies, and iden-
tified a hitherto-unknown role of 5-HT as a major regulator of
mitochondrial biogenesis and function in cortical neurons, via a
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5-HT2A receptor-mediated recruitment of the SIRT1–PGC-1α
axis. The effects of 5-HT on mitochondrial biogenesis and
function play a central role in the ability of 5-HT to promote
neuronal survival in response to excitotoxic or oxidative insults.
Our results highlight an important function of 5-HT in the
modulation of mitochondrial biogenesis and function in neurons,
which facilitates stress adaptation and survival.
Results
Mitochondrial Biogenesis and Function Are Regulated by 5-HT. We
examined the influence of the monoamine 5-HT on mitochon-
drial mass in cortical neurons in vitro by assessing mitotracker
staining, which revealed a significant increase in staining in-
tensity in 5-HT–treated neurons (Fig. 1 A–C). Immunofluores-
cence intensity measurements for the mitochondrial voltage-
dependent anion channel (VDAC) demonstrated significantly
increased levels following exposure to 5-HT (Fig. 1 D and E).
Elevated levels of the mitochondrial outer (VDAC) and inner
(cytochrome C; Cyt C) membrane marker proteins also corrob-
orated the increased mitochondrial mass noted following 5-HT
treatment (Fig. 1 F–H and SI Appendix, Fig. S1 A–C). Mito-
chondrial biogenesis is modulated by the expression of nuclear-
and mitochondrial-encoded genes, which is orchestrated by
master regulators such as PGC-1α, nuclear respiratory factor
(Nrf1), and transcription factor A mitochondrial (TFAM) that
mediate mtDNA replication. PGC-1α (Fig. 1G and SI Appendix,
Fig. S1D) and TFAM (Fig. 1H and SI Appendix, Fig. S1E) pro-
tein levels were significantly elevated following 5-HT exposure.
The 5-HT treatment also evoked a dose-dependent up-
regulation of Ppargc1a (Fig. 1I), Tfam (Fig. 1J), and Nrf1 (SI
Appendix, Fig. S1F) transcripts. A dose-dependent increase in
mtDNA content (Fig. 1K) confirmed enhanced mitochondrial
biogenesis in response to 5-HT treatment. Time-course analysis
(SI Appendix, Fig. S1 G–Q) indicated a significant increase in
PGC-1α expression, at the mRNA (SI Appendix, Fig. S1 G–J)
and protein (SI Appendix, Fig. S1K) levels, with transcriptional
changes noted as early as 4 h after 5-HT treatment. We also
observed increased expression of Ppargc1a, Tfam, Nrf1, and Cycs
at the 6-h time point (SI Appendix, Fig. S1H). The time-course
analysis indicates two phases of transcriptional regulation of
mitochondrial biogenesis regulatory genes, with the first phase
noted as early as 4–6 h, with a return to baseline and a second
phase observed at 48 h (Ppargc1a, SI Appendix, Fig. S1 I and J;
and Nrf1, SI Appendix, Fig. S1 L and N) or 72 h (Tfam; SI Ap-
pendix, Fig. S1 L and M), following onset of 5-HT treatment.
This preceded the 5-HT–evoked increase in mtDNA (SI Appen-
dix, Fig. S1 O and P), highlighting the induction of a transcrip-
tional program that may mediate 5-HT–dependent mitochondrial
biogenesis.
Fig. 1. Mitochondrial biogenesis and function are regulated by 5-HT. (A) Shown is a schematic depicting the treatment paradigm with 5-HT (100 μM) in
cultured cortical neurons, commencing at day in vitro (DIV) 7 until DIV 13. (B) Shown are representative confocal images for Mitotracker Green staining in
control (Ctl) and 5-HT–treated (100 μM) neurons, with nuclei counterstained with Hoechst 33342 (blue). (Scale bars: 30 μm; magnification: 60×.) (C) Quan-
titative analysis of fluorescence intensity represented as mitotracker (mito) intensity per micrometer of neurite ± SEM (n = 56 neurons in control, n =
59 neurons for 5-HT treatment, mean values ± SEM compiled across N = 3). *P < 0.05 (compared with control, unpaired Student’s t test). (D) Shown are
representative immunofluorescence images for VDAC (green), neuronal marker MAP2 protein (red), and merge (yellow) from control and 5-HT–treated
(100 μM) neurons. Nuclei are counterstained with Hoechst 33342 (blue). (Scale bars: 50 μm; magnification: 60×.) (E) Quantitative analyses for VDAC fluo-
rescence intensity are represented as fold change in VDAC expression compared with control ± SEM (n = 86 neurons in control, n = 78 neurons for 5-HT
treatment, mean values ± SEM compiled across N = 3). *P < 0.05 (compared with control, unpaired Student’s t test). (F) Shown is a schematic depicting
treatment of neurons with increasing doses of 5-HT (10, 50, and 100 μM). (G and H) Shown are representative immunoblots for PGC-1α, VDAC, and tubulin as
the loading control (G) and TFAM, Cyt C, and tubulin as loading control (H) in neurons treated with increasing doses of 5-HT (50 and 100 μM). (I and J)
Quantitative PCR (qPCR) analysis for mRNA expression of key regulators of mitochondrial biogenesis Ppargc1a (I) and Tfam (J) are represented as fold change
of control ± SEM (representative results from n = 4 per treatment group/N = 3). *P < 0.05 (compared with control, one-way ANOVA, Tukey’s post hoc test). (K)
qPCR analyses for mtDNA levels are represented as relative mtDNA content ± SEM (representative results from n = 4–6 per treatment group/N = 3). *P < 0.05
(compared with control, one-way ANOVA, Tukey’s post hoc test). (L) Quantitation of ATP levels expressed as fold change of control ± SEM (representative
results from n = 4 per treatment group/N = 4). *P < 0.05 (compared with control, one-way ANOVA, Tukey’s post hoc test). (M) Shown is a schematic for the
treatment paradigm with 5-HT (100 μM) (DIV 10–13) for Seahorse analysis of cellular respiration. (N) Shown is a representative Seahorse plot for control and 5-
HT–treated cortical neurons, with measurements of OCR (normalized to cell numbers per well), baseline, and following treatment of cells with oligomycin
(Olig), FCCP, and rotenone (Rot), as indicated. (O–R) Quantitative analysis of the effects of 5-HT on basal respiration (O), ATP-coupled respiration (P), maximal
respiration (Q), and spare respiratory capacity (R) expressed as fold change of control ± SEM (compiled results from n = 5 per treatment group/N = 3). *P <
0.05 (compared with control, unpaired Student’s t test).
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We next sought to determine if 5-HT altered bioenergetics in
cortical neurons and observed that 5-HT treatment resulted in
enhanced cellular ATP levels in a dose-dependent (Fig. 1L) and
time-dependent (SI Appendix, Fig. S1 O and Q) manner. These
effects appeared to be selective to 5-HT, as neither norepinephrine
(NE) nor dopamine (DA) influenced mtDNA content (SI Appendix,
Fig. S1 R and S) or ATP (SI Appendix, Fig. S1 R and T) levels in
cortical neurons. On assaying for oxidative phosphorylation
(OXPHOS) and electron transport chain efficiency, by measuring
oxygen-consumption rate (OCR) (Fig. 1 M and N), we found a
robust increase in basal OCR (∼50%) (Fig. 1O) in 5-HT–treated
cortical neurons, accompanied by an increase in ATP-coupled res-
piration (Fig. 1P). Treatment with the mitochondrial uncoupler
FCCP revealed a higher maximal respiration (Fig. 1Q) in 5-HT–
treated cortical neurons, concomitant with an increase in spare re-
spiratory capacity (Fig. 1R), compared with controls. These findings
indicate that, in addition to modulating mitochondrial biogenesis, 5-
HT also exerts an important regulatory control on OXPHOS and
leads to enhanced mitochondrial function in cortical neurons.
Effects of 5-HT on Mitochondrial Biogenesis and Function Are Mediated
via the 5-HT2A Receptor.We carried out pharmacological and genetic
perturbation studies to determine the contribution of specific 5-HT
receptors to the effects of 5-HT on mitochondria. Cortical neurons
express several 5-HT receptors, among which the 5-HT2A and 5-
HT1A receptors are expressed at high levels (SI Appendix, Fig. S2 A
and B). The 5-HT2A receptor antagonist MDL100,907 completely
inhibited the 5-HT–evoked increase in mtDNA content (Fig. 2 A
and B) and Ppargc1a expression. (Fig. 2C). Furthermore, the 5-HT–
mediated induction of ATP levels was also prevented by treatment
with MDL100,907 (Fig. 2D). A role for 5-HT2A receptors in reg-
ulation of mitochondrial biogenesis and energetics was further
supported by evidence of a dose-dependent increase in mtDNA
(Fig. 2 E and F), Ppargc1a expression (Fig. 2G), and ATP levels
(Fig. 2H) following treatment with the 5-HT2A receptor agonist 2,5-
dimethoxy-4-iodoamphetamine (DOI). In addition to significant
increases in mitochondrial biogenesis and function evoked by DOI,
a 5-HT2A receptor agonist with hallucinogenic effects, we also
noted that a nonhallucinogenic 5-HT2A receptor agonist lisuride (SI
Appendix, Fig. S2C) could also increase mtDNA (SI Appendix, Fig.
S2D), Ppargc1a expression (SI Appendix, Fig. S2E), and ATP levels
(SI Appendix, Fig. S2F). Treatment with the 5-HT1A receptor an-
tagonist WAY100,635 did not alter the 5-HT–mediated increase in
mtDNA (SI Appendix, Fig. S2 G and H) and ATP (SI Appendix,
Fig. S2I) levels. To address whether 5-HT2A receptor stimulation
with DOI influences mitochondrial respiration, we measured OCR
(Fig. 2 I and J). Cortical neurons treated with DOI exhibited sig-
nificant increases in both basal OCR (Fig. 2K) and ATP-coupled
respiration (Fig. 2L), accompanied by enhanced maximal respiration
(Fig. 2M) and spare respiratory capacity (Fig. 2N). Importantly, the
effects of 5-HT on mitochondrial biogenesis and OXPHOS were
recapitulated by treatment with the 5-HT2A receptor agonist DOI.
We further characterized the contribution of the 5-HT2A receptor,
using cortical neurons derived from 5-HT2A receptor knockouts (5-
HT2A
−/−), compared with wild-type (WT) and 5-HT2A
−/−Res cortical
cultures (Fig. 2 O and P and SI Appendix, Fig. S2 J and K). The 5-
HT–mediated increase in mtDNA content (Fig. 2Q) and Ppargc1a
expression (Fig. 2R) was completely abrogated in 5-HT2A
−/− cortical
neurons and was restored in 5-HT2A
−/−Res cells, wherein a viral-
based gene delivery of rAAV8–CaMKIIα–GFP–Cre was utilized
to rescueHtr2a expression in cortical neurons (SI Appendix, Fig. S2 J
and K). Furthermore, the induction of ATP levels noted following 5-
HT treatment to WT neurons was absent in cortical cultures derived
from 5-HT2A receptor knockouts and was reinstated on rescue of 5-
HT2A receptor expression (Fig. 2S). Together, these results illustrate
that the 5-HT2A receptor is necessary for the effects of 5-HT on
mitochondrial biogenesis and energetics.
Having identified the 5-HT2A receptor as a key determinant of
the effects of 5-HT on mitochondria, we next sought to delineate
the contribution of specific downstream signaling pathways.
Cortical neurons were incubated with 5-HT in the presence of
U73122, U0126, and LY294002, specific inhibitors for the
phospholipase C (PLC), MEK, and phosphatidylinositol 3-kinase
(PI3K) signaling pathways, respectively (Fig. 2 T and U and SI
Appendix, Fig. S2 L–P). The 5-HT treatment resulted in robust
activation of phospho-PLC (pPLC) (Fig. 2U and SI Appendix,
Fig. S2M) and phospho-ERK (pERK) (Fig. 2U and SI Appendix,
Fig. S2N), but not of phospho-Akt (pAkt) (SI Appendix, Fig. S2
O and P), which lies downstream of PI3K. The 5-HT–mediated
increase in mtDNA content (Fig. 2V) and Ppargc1a expression
(Fig. 2W) were partially blocked by both PLC and MEK inhibitors,
but not by PI3K inhibition (Fig. 2 V and W). These findings im-
plicate signaling via the PLC and MAPK/ERK cascades in the ef-
fects of 5-HT on mitochondrial biogenesis. Collectively, these
results indicate that 5-HT via the 5-HT2A receptor and the PLC and
MAPK signaling pathways modulate mitochondrial biogenesis.
Sirt1 Is Required for the Effects of 5-HT on Mitochondrial Biogenesis
and Function. SIRT1, a NAD+-dependent deacetylase, is well
established to induce mitochondrial biogenesis and functions by
its ability to regulate transcription involving PGC-1α (6). In
cortical neurons, we observed an up-regulation of Sirt1mRNA as
early as 4 h (Fig. 3 A and B), with a return to baseline noted at
8 h after commencement of 5-HT treatment. We also noted a
sustained up-regulation of Sirt1 mRNA observed at 48 h onward
(Fig. 3C), with a commensurate increase in SIRT1 protein levels
at 48 h (Fig. 3 D and E). The transcriptional up-regulation of
Sirt1 by 5-HT was blocked by coadministration of the 5-HT2A
receptor antagonist MDL100,907 (SI Appendix, Fig. S3 A and B)
and mimicked by the 5-HT2A receptor agonist DOI (SI Appendix,
Fig. S3 C and D). We investigated the possible involvement of
SIRT1 in the actions of 5-HT on mitochondria by treating cor-
tical neurons with 5-HT in the presence of EX-527, a selective
chemical inhibitor of SIRT1 activity (Fig. 3F). EX-527 treatment
abrogated the 5-HT–induced increase in mtDNA content (Fig.
3G) and mitochondrial mass in neurites (Fig. 3 H and I). Fur-
thermore, coadministration of EX-527 with 5-HT failed to ex-
hibit the 5-HT–evoked up-regulation of Ppargc1a (Fig. 3J), Tfam
(Fig. 3K), Nrf1 (SI Appendix, Fig. S3 E and F), and Cycs (SI
Appendix, Fig. S3G). We then examined the consequences of
SIRT1 inhibition and found that the 5-HT–mediated increase in
ATP levels was abrogated in the presence of EX-527 (Fig. 3L).
To further ascertain the contribution of SIRT1 to the regulation
of ATP levels by 5-HT, we used cortical neurons derived from
SIRT1 conditional knockout (Sirt1cKO) embryos (Fig. 3M).
Treatment with 5-HT failed to induce cellular ATP levels in
cortical neurons from Sirt1cKO, compared with WT controls,
thus demonstrating an essential role for SIRT1 in mediating the
effects of 5-HT (Fig. 3N). We next examined the influence of 5-
HT on cortical neurons derived from SirT1lox/lox embryos and in
vitro transduced with adeno-associated virus (AAV) Cre− or
AAV Cre+ to yield control (SirT1lox/lox) or SIRT1 loss-of-
function (SirT1co/co) neurons, respectively (Fig. 3O and SI Ap-
pendix, Fig. S3H). Treatment with 5-HT did not alter gene ex-
pression of Ppargc1a (Fig. 3P), Tfam (Fig. 3Q), Nrf1 (SI
Appendix, Fig. S3I), or Cycs (SI Appendix, Fig. S3J) in the ab-
sence of SIRT1 (SirT1co/co), in contrast to the robust up-
regulation noted in control SirT1lox/lox cortical neurons. To-
gether, our pharmacological and genetic perturbation studies
illustrate the role of SIRT1 in mediating the mitochondrial ef-
fects of 5-HT.
Neuroprotective Effects of 5-HT Against Excitotoxic and Oxidative
Stress Are Mediated via the 5-HT2A Receptor and SIRT1. Given that
5-HT exerts robust effects on mitochondria, which are major
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sites of reactive oxygen species (ROS) production and scav-
enging, we next examined 5-HT effects on cellular ROS levels.
We assessed the influence of 5-HT both at baseline and in the
context of challenge with excitotoxic (kainate) (Fig. 4 A and B)
and oxidative (hydrogen peroxide; H2O2) stressors (Fig. 4 A
and B). Fluorometric analysis of cellular ROS levels indicated
a baseline reduction following 5-HT treatment (Fig. 4 C and
D) compared with control cortical neurons. Furthermore, 5-
HT pretreatment robustly attenuated the increased ROS lev-
els observed following treatment with kainate (Fig. 4 B and C)
Fig. 2. Mitochondrial effects of 5-HT are mediated via the 5-HT2A receptor. (A) Shown is a schematic depicting the treatment paradigm for cortical neuron cultures
with 5-HT (100 μM), MDL100,907 (10 μM), and 5-HT+MDL100,907 for 72 h commencing on DIV 10. (B–D) Quantitation of mtDNA (B), Ppargc1amRNA (C), and ATP (D)
levels in cortical neurons treated with 5-HT in the presence or absence of MDL100,907 (MDL) are represented as fold change of control (Ctl) ± SEM [representative
results from n = 4 per treatment group/N = 2 (mtDNA and ATP) and N = 3 (Ppargc1a mRNA)]. *P < 0.05 (compared with control); $P < 0.05 (compared with 5-HT–
treated group); two-way ANOVA, Tukey’s post hoc test. (E) Shown is a schematic depicting the treatment paradigm for cortical neurons with increasing doses of DOI
(5 and 10 μM) from DIV 7 to 13. (F–H) Quantitation of mtDNA (F), Ppargc1amRNA (G), and ATP (H) levels in neurons treated with DOI are represented as fold change
of control ± SEM (representative results from n = 4 per treatment group/N = 2). *P < 0.05 (compared with control, one-way ANOVA, Tukey’s post hoc test). (I) Shown
is a schematic depicting the treatment paradigm of cortical neurons with DOI (10 μM) for Seahorse analysis of cellular respiration starting DIV 10. (J) Shown is a
representative Seahorse plot for control and DOI-treated cortical neurons, with measurements of OCR (normalized to cell numbers per well) at baseline and following
treatment with oligomycin (Olig), FCCP, and rotenone (Rot), as indicated. (K–N) Bar graphs depict quantitative analysis of the effects of DOI on basal respiration (K),
ATP-coupled respiration (L), maximal respiration (M), and spare respiratory capacity (N) expressed as fold change of control ± SEM (compiled results from n = 4 or
5 per treatment group/N = 3). *P < 0.05 (compared with control, unpaired Student’s t test). (O) Shown is a schematic depicting the treatment paradigm of WT, 5-
HT2A
−/−, and 5-HT2A
−/−Res cortical neurons with 5-HT (100 μM). (P) Shown are representative images for 5-HT2A receptor immunofluorescence (green) from WT, 5-
HT2A
−/−, and 5-HT2A
−/−Res cortical neuron cultures with nuclei counterstained with Hoechst 33342 (blue). (Scale bars: 50 μm; magnification: 60×.) (Q–S) Graphs depict
quantitative analysis for mtDNA (Q), Ppargc1a mRNA (R), and ATP (S) levels in WT, 5-HT2A
−/−, and 5-HT2A
−/−Res cortical neurons treated with 5-HT, and results are
represented as fold change of WT ± SEM (representative results from n = 4 per treatment group/N = 2). *P < 0.05 (compared with WT); $P < 0.05 (compared with
WT+5-HT); €P < 0.05 (compared with 5-HT2A
−/−Res); two-way ANOVA, Tukey’s post hoc test. (T) Shown is a schematic depicting the treatment paradigm of cortical
neurons with 5-HT (100 μM) in the presence or absence of signaling inhibitors for PLC (U73122; 5 μM), MEK (U0126; 10 μM), and PI3K (LY294002; 10 μM). (U) Shown
are representative immunoblots for pPLC and PLC levels in cortical neurons treated with 5-HT in the presence or absence of the PLC inhibitor U73122 and for pERK
and ERK levels in cortical neurons treated with 5-HT in the presence or absence of the MEK inhibitor U0126. Actin and tubulin immunoblots serve as the loading
controls. (V andW) Quantitative analysis for mtDNA (V) and Ppargc1amRNA (W) levels in cortical neurons treated with 5-HT in the presence or absence of PLC, MEK,
and PI3K inhibitors are represented as fold change of control ± SEM (representative results from n = 4 per treatment group/N = 2). *P < 0.05 (compared with control);
$P < 0.05 (compared with 5-HT–treated group); €P < 0.05 (compared with LY294002 group); two-way ANOVA, Tukey’s post hoc test.
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or H2O2 (Fig. 4 B and D). Up-regulation of ROS scavenging
enzymes superoxide dismutase 2 (Sod2) and catalase (Cat),
which are known to be regulated by SIRT1/PGC-1α (11, 12),
corroborated these findings and suggests putative mechanisms
for 5-HT–mediated reduction of cellular ROS (SI Appendix,
Fig. S4 A–C).
We then sought to examine potential neuroprotective effects
of 5-HT in the context of kainate-mediated excitotoxicity or
H2O2-mediated oxidative damage (Fig. 4A). Cell-survival assays,
using the cell viability marker MTT, revealed that cortical neu-
ronal survival was significantly reduced by kainate (Fig. 4E) and
H2O2 (Fig. 4F) treatment and was attenuated in a dose-dependent
fashion in 5-HT–pretreated cortical cultures. These neuroprotective
effects of 5-HT were mimicked by pretreatment with DOI, which
also enhanced cell survival to excitotoxic or oxidative insults (SI
Appendix, Fig. S4D–F). Given our results of a role for SIRT1 in the
mitochondrial effects of 5-HT, we examined the contribution of
SIRT1 to the neuroprotective action of 5-HT. Cortical neuronal
cultures were pretreated with 5-HT in the presence/absence of the
SIRT1 inhibitor EX-527, followed by exposure to increasing doses
of either kainate (Fig. 4 G and H) or H2O2 (Fig. 4 G and I). EX-
527 prevented the 5-HT–mediated neuroprotective effects in re-
sponse to challenge with escalating doses of kainate (Fig. 4H) and
H2O2 (Fig. 4I). The neuroprotective actions of 5-HT were observed
over a wide range of kainate and H2O2 doses, and SIRT1 inhibition
prevented these effects. The enhanced cell viability noted in cortical
neurons pretreated with the 5-HT2A receptor agonist DOI on
kainate or H2O2 challenge was attenuated by EX-527 (SI Appendix,
Fig. S4G–I). These findings indicate that SIRT1 plays an important
role in contributing to the neuroprotective effects of 5-HT and the
5-HT2A receptor agonist DOI in the context of excitotoxic and
oxidative stress. This was further confirmed via evidence from
Sirt1cKO cortical cultures, which, unlike WT cortical neurons, failed
to exhibit the improved cell viability noted on 5-HT pretreatment
before kainate-mediated (Fig. 4 J and K) or H2O2-mediated (Fig. 4 J
and L) challenge. Together, these results indicate that 5-HT,
via the 5-HT2A receptor and the sirtuin SIRT1, exerts robust
neuroprotective effects against excitotoxic and oxidative cell death
and damage.
Fig. 3. SIRT1 is required for the effects of 5-HT on mitochondria. (A) Shown is a schematic depicting the treatment paradigm of neurons with 5-HT (100 μM)
for 4, 6, 8, 48, and 72 h and 6 d and lysed synchronously at DIV 13. (B and C) qPCR analysis for Sirt1 mRNA expression is expressed as fold change of control
(Ctl) ± SEM (representative results from n = 4 per treatment group/N = 2). *P < 0.05 (compared with control, one-way ANOVA, Tukey’s post hoc test). (D)
Shown is a representative immunoblot for SIRT1 protein expression and the loading control tubulin from control and 5-HT–treated (100 μM) cortical neurons
at 48 h. (E) Quantitative densitometric analysis of SIRT1 levels normalized to tubulin. Results are expressed as fold change of control ± SEM (compiled results
from n = 6 per treatment group/N = 2). *P < 0.05 (compared with control, unpaired Student’s t test). (F) Shown is a schematic depicting the treatment
paradigm of neurons with 5-HT (100 μM) in the presence or absence of SIRT1 inhibitor EX-527 (10 μM) commencing on DIV 10. (G) Quantitation of mtDNA in 5-
HT–treated cortical neurons in the presence or absence of EX-527 are represented as fold change of control ± SEM (representative results from n = 4 per
treatment group/N = 3). *P < 0.05 (compared with control); $P < 0.05 (compared with 5-HT–treated group); two-way ANOVA, Tukey’s post hoc test. (H) Shown
are representative confocal images for Mitotracker Green staining in control (Ctl) and 5-HT–treated cortical neurons in the presence and absence of EX-527.
(Scale bars: 50 μm; magnification: 60×.) (I) Quantitative analysis of fluorescence intensity represented as mitotracker (Mito) intensity per micrometer of
neurite ± SEM (n = 39 neurons in control group, n = 47 neurons in 5-HT–treated group, n = 44 neurons in 5-HT+EX-527 group, and n = 33 neurons in EX-
527 group, mean ± SEM compiled across N = 2). *P < 0.05 (compared with control); $P < 0.05 (compared with 5-HT–treated group); two-way ANOVA, Tukey’s
post hoc test. (J–L) Graphs depict quantitation of Ppargc1a (J) and Tfam (K) mRNA and cellular ATP (L) levels in cortical neurons treated with 5-HT in the
presence or absence of EX-527 and represented as fold change of control ± SEM [representative results from n = 4 per treatment group/N = 4 (Ppargc1a
mRNA and ATP) and N = 2 (Tfam mRNA)]. *P < 0.05 (compared with control); $P < 0.05 (compared with 5-HT–treated group); two-way ANOVA, Tukey’s post
hoc test. (M) Shown is a schematic depicting the treatment paradigm for cortical neuron cultures from Sirt1cKO and WT mice, with 5-HT (100 μM) com-
mencing on DIV 7. (N) Quantitative analyses of ATP levels in WT and Sirt1cKO cortical neuron cultures following 5-HT treatment are represented as fold
change of WT ± SEM (representative results from n = 4 per treatment group/N = 2). *P < 0.05 (compared with WT); $P < 0.05 (compared with WT+5-HT); two-
way ANOVA, Tukey’s post hoc test. (O) Shown is a schematic depicting the treatment paradigm for cortical neuron cultures derived from SirT1lox/lox embryos
and then transduced in vitro on DIV 2 with rAAV8–CamKIIα–GFP (AAV-Cre−) or rAAV8–CamKIIα–GFP–Cre (AAV-Cre+) to yield control cortical neurons
(SirT1lox/lox) or cortical neurons with loss of function of SIRT1 (SirT1co/co). SirT1lox/lox and SirT1co/co cortical neuron cultures were then treated with vehicle
or 5-HT (100 μM) commencing on DIV 7. (P and Q) Graphs depict quantitation of Ppargc1a (P) and Tfam (Q) mRNA expression in SirT1lox/lox and SirT1co/co
cortical neurons, in the presence or absence of 5-HT and represented as fold change of control ± SEM (representative results from n = 6 per treatment
group/N = 2). *P < 0.05 [compared with Ctl (SirT1lox/lox)]; $P < 0.05 [compared with 5-HT (SirT1lox/lox)]; two-way ANOVA, Tukey's post hoc test.
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In Vivo Regulation of Cortical Mitochondrial DNA Content, Gene and
Protein Expression, Mitochondrial OCR, and ATP by 5-HT. Given that
we noted robust effects of 5-HT, via the 5-HT2A receptor, on
mitochondrial biogenesis and function in cortical neurons in
vitro, we next sought to examine whether DOI-mediated stimu-
lation of the 5-HT2A receptor led to regulation of mitochondrial
biogenesis, gene/protein expression, and cellular ATP levels in
vivo (Fig. 5A). Subchronic (72 h) treatment with DOI resulted in
a significant increase in mtDNA content (Fig. 5B); gene ex-
pression of Ppargc1a, Sirt1, Nrf1, Tfam, and Cycs (Fig. 5C) in the
rat neocortex; and enhanced cortical protein levels of SIRT1,
TFAM, Cyt C, ATP5A, and VDAC (Fig. 5D and SI Appendix,
Fig. S5 A–F). These transcriptional changes were also observed
in vivo in DOI-treated C57BL/6NCrl/Cri mice, with a rapid in-
duction of Ppargc1a, Sirt1, and Tfam (SI Appendix, Fig. S5 H–K)
at 2 h, with a return to baseline at 24 h, and a subsequent in-
crease noted at 48 and 72 h. We also noted enhanced cortical
cellular ATP levels in DOI-treated rats compared with vehicle-
treated controls (Fig. 5E). Seahorse analysis (SI Appendix, Fig.
S5G) performed on isolated mitochondria derived from cortices
of vehicle- and DOI-treated rats revealed enhanced state-2 (via
complex-I/II) and state-3 (complex II-dependent) respiration
(Fig. 5F) and ATP production rate (Fig. 5G) following DOI
administration. As these rates were normalized to the amount of
mitochondria used in the assay, it was suggestive of higher complex
I and II activity and OXPHOS efficiency following 5-HT2A receptor
stimulation. These in vivo observations recapitulated the effects of
DOI on mitochondria noted in cortical neuronal cultures.
To address whether the in vivo effects of 5-HT2A receptor
stimulation with DOI are also triggered by 5-HT, we directly
delivered 5-HT (10 μM, 7 d; Fig. 5H) into the neocortex of
Sprague–Dawley rats using Alzet osmotic minipumps. Intra-
cortical infusion of 5-HT resulted in significant increases in
mtDNA (Fig. 5I) and cellular ATP (Fig. 5J) levels, indicating
Fig. 4. Neuroprotective effects of 5-HT against excitotoxic and oxidative stress are mediated via SIRT1. (A) Shown is a schematic depicting the treatment
paradigm of neurons with 5-HT (50 or 100 μM) pretreatment commencing on DIV 7 followed by exposure to the excitotoxic insult of kainate (100 and 200 μM)
or oxidative stress through H2O2 (100 and 200 μM) on DIV 13, and analysis of cellular ROS or cell survival via the MTT assay. (B) Shown are representative
confocal images of carboxy-H2DCFDA staining (green) to measure cellular ROS in neurons treated with 5-HT (100 μM), kainate (100 μM), H2O2 (200 μM), 5-
HT+kainate, or 5-HT+H2O2. Nuclei are counterstained with Hoechst 33342 (blue). Shown are the differential interference contrast (DIC) images of cortical
neurons across treatment conditions. (Scale bars: 50 μm; magnification: 60×.) (C and D) Fluorometric quantitation of staining intensity of cellular ROS (car-
boxy-H2DCFDA) normalized to protein content per well and represented as percent of control ± SEM (representative results from n = 4 per treatment group/
N = 2). *P < 0.05 (compared with control); ¥P < 0.05 (compared with kainate-treated group); £P < 0.05 (compared with H2O2-treated group); (two-way
ANOVA, Tukey’s post hoc test). (E and F) Graphs depict cell viability assessed by the MTT assay in cortical neurons challenged with kainate (100 or 200 μM) or
H2O2 (100 or 200 μM) with or without pretreatment with 5-HT (50 or 100 μM). Results are expressed as percent of control cell viability ± SEM (representative
results from n = 3 per treatment group/N = 2). *P < 0.05 (compared with control); ¥P < 0.05 (compared with 100 μM kainate-treated group); ¥¥P < 0.05
(compared with 200 μM kainate-treated group); £P < 0.05 (compared with 100 μM H2O2-treated group); ££P < 0.05 (compared with 200 μM H2O2-treated
group); &P < 0.05 (compared with 50 μM 5-HT–treated group); @P < 0.05 (compared with 100 μM 5-HT–treated group); two-way ANOVA, Tukey’s post hoc test.
(G) Shown is a schematic depicting the treatment paradigm of neurons with 5-HT (100 μM) in the presence or absence of the SIRT1 inhibitor EX-527 (10 μM),
followed by challenge with increasing doses of kainate or H2O2 (0–1,000 μM) and analysis of cell viability using the MTT assay. (H) Shown is a line graph for cell
viability of cortical neurons in response to increasing doses of kainate (0–1,000 μM) with treatment groups of kainate (blue), 5-HT+kainate (red), EX-
527+kainate (purple), and 5-HT+EX-527+kainate (green), expressed as percent of control cell viability ± SEM (representative results from n = 3 per treat-
ment group/N = 2). ¥P < 0.05 (compared with kainate-treated group); @P < 0.05 (compared with 5-HT+EX-527+kainate-treated group); three-way ANOVA,
Tukey’s post hoc test. (I) Shown is a line graph for cell viability of cortical neurons in response to increasing doses of H2O2 (0–1,000 μM) with treatment groups
of H2O2 (blue), 5-HT+H2O2 (red), EX-527+H2O2 (purple), and 5-HT+EX-527+H2O2 (green), expressed as percent of control cell viability ± SEM (representative
results from n = 3 per treatment group/N = 2). £P < 0.05 (compared with H2O2-treated group);
&P < 0.05 (compared with 5-HT+EX-527+H2O2-treated group);
three-way ANOVA, Tukey’s post hoc test. (J) Shown is a schematic depicting the treatment paradigm of cortical neuron cultures derived fromWT and Sirt1cKO
embryos, with 5-HT (50 μM) treatment commencing on DIV 7, followed by a challenge with kainate (100 μM) or H2O2 (200 μM) on DIV 13 and analysis of cell
viability. (K and L) Graph depicts cell viability of WT, WT+5-HT, Sirt1cKO, and Sirt1cKO+5-HT cortical neurons left untreated (Ctl) or challenged with kainate
(K) or H2O2 (L) and expressed as percent of WT-Ctl cell viability ± SEM (representative results from n = 3 per treatment group/N = 2). *P < 0.05 (compared with
WT-Ctl); **P < 0.05 (compared with Sirt1cKO-Ctl); ¥P < 0.05 (compared with WT+kainate); @P < 0.05 (compared with WT+5-HT+kainate); £P < 0.05 (compared
with WT+H2O2);
&P < 0.05 (compared with WT+5-HT+H2O2); three-way ANOVA, Tukey’s post hoc test.
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that 5-HT also modulates mitochondrial mass and function in
vivo. We next sought to modulate 5-HT levels in vivo, via acti-
vation of Pet1-positive serotonergic neurons (SI Appendix, Fig.
S5 L and M) expressing the hM3Dq designer receptors exclu-
sively activated by designer drugs (DREADD) coupled to Gq
signaling in a bigenic hM3Dq/Pet1–Cre mouse line. hM3Dq/
Pet1–Cre mice received the DREADD agonist clozapine-N-oxide
(CNO) (3 mg/kg), which resulted in enhanced expression of
c-Fos, a marker of neuronal activation within serotonergic neu-
rons (SI Appendix, Fig. S5 N and O). We then determined the
influence of chemogenetic activation of Pet1–Cre-positive sero-
tonergic neurons (CNO; 3 mg/kg, once daily for 10 d) (Fig. 5K
and SI Appendix, Fig. S1P) on mitochondrial biogenesis and
function in the prefrontal cortex (PFC), which was selected due
to the abundant expression of 5-HT2A receptors in this neo-
cortical region. We observed a significant increase in mtDNA
(Fig. 5L) and cellular ATP (Fig. 5M) levels in CNO-treated
hM3Dq/Pet1–Cre mice compared with vehicle-treated controls.
Western blot analysis revealed significant increases in SIRT1 (Fig.
5N and SI Appendix, Fig. S5Q), VDAC (Fig. 5N and SI Appendix,
Fig. S5R), ATP5A (Fig. 5N and SI Appendix, Fig. S5S), and TFAM
(Fig. 5N and SI Appendix, Fig. S5T) and a trend (P = 0.09) toward
an increase for Cyt C (Fig. 5N and SI Appendix, Fig. S5U) protein
expression in the CNO-treated hM3Dq/Pet1–Cre group. Collec-
tively, these results indicate that both 5-HT infusion into the cortex
in a rat model and chemogenetic activation of serotonergic neurons
in a mouse model can evoke changes in mitochondrial biogenesis
and function in vivo.
We then addressed the contribution of SIRT1 to the effects of
5-HT2A receptor stimulation on mtDNA, gene expression of
mitochondrial regulators, and ATP levels in vivo using condi-
tional, cortical SIRT1 knockout (Sirt1cKO: Emx1–Cre; Sirt1−/−)
mice (Fig. 5O). While subchronic DOI administration resulted in
a significant induction of mtDNA levels in WT animals, this was
lost in Sirt1cKO mice (Fig. 5P). Furthermore, DOI treatment
evoked an up-regulation of Ppargc1a, Tfam, and Cycs, in WT, but
not in Sirt1cKO, mice (Fig. 5 Q–S). Furthermore, the DOI-
mediated increase in cellular ATP levels was completely abro-
gated in Sirt1cKO mice (Fig. 5T). Collectively, these results es-
tablish that 5-HT2A receptor stimulation induces mitochondrial
biogenesis and function through transcriptional control exerted
by SIRT1.
Discussion
Our findings demonstrate that 5-HT regulates both mitochon-
drial biogenesis and function in cortical neurons, via the 5-HT2A
Fig. 5. In vivo regulation of cortical mitochondrial DNA content, gene and protein expression, mitochondrial OCR, and ATP by 5-HT. (A) Shown is a schematic
of the treatment paradigm for Sprague–Dawley rats with the 5-HT2A receptor agonist DOI (2 mg/kg) or vehicle (Veh; saline). (B and C) Quantitation of mtDNA
levels (B) and gene expression of Ppargc1a, Sirt1, Tfam, Nrf1, and Cycs (C) within the cortex of saline- and DOI-treated rats expressed as fold change of
vehicle ± SEM (n = 8–11 animals per group). *P < 0.05 (compared with vehicle, unpaired Student’s t test). (D) Shown are representative immunoblots for SIRT1,
TFAM, Cyt C, ATP5A, VDAC, and actin as loading control in cortices derived from vehicle- and DOI-treated animals. (E) Quantitation of cellular ATP levels in
cortices derived from vehicle- and DOI-treated Sprague–Dawley rats are represented as fold change of control ± SEM (n = 8–11 animals per group). *P < 0.05
(compared with vehicle, unpaired Student’s t test). (F and G) Shown is the quantitation of state-2 (via complex-I/II) and state-3 (complex II-dependent) res-
piration (F) and ATP production rate (G) on isolated mitochondria (10 μg) derived from the PFC of vehicle- and DOI-treated Sprague–Dawley rats (A), based on
Seahorse analysis, and expressed as fold change of vehicle ± SEM (n = 5 per treatment group/N = 1). *P < 0.05 (compared with vehicle, unpaired Student’s
t test). (H) Shown is a schematic of the surgical treatment paradigm to deliver 5-HT (10 μM) or vehicle via osmotic minipumps directly into the neocortex for a
duration of 7 d. (I and J) Quantitation for relative mtDNA content (I) and cellular ATP levels (J) expressed as fold change of vehicle ± SEM (representative
results from n = 6 per treatment group/N = 1). *P < 0.05 (compared with vehicle, unpaired Student’s t test). (K) Shown is a representative paradigm for
chemogenetic activation of serotonergic neurons using hM3Dq/Pet1–Cre bigenic mice and systemic administration of the DREADD agonist CNO (3 mg/kg,
once daily for 10 d) with euthanization (S) 2 h following the final CNO administration. (L andM) Quantitation for relative mtDNA content (L) and cellular ATP
levels (M) in the PFC of vehicle- and CNO-administered hM3Dq/Pet1–Cre mice is expressed as fold change of vehicle ± SEM (representative results from n = 6–
8 per treatment group/N = 1). *P < 0.05 (compared with vehicle, unpaired Student’s t test). (N) Shown are representative immunoblots for SIRT1, VDAC,
ATP5A, TFAM, Cyt C, and actin as loading control in the PFC derived from vehicle- and CNO-administered hM3Dq/Pet1–Cre mice. (O) Shown is a schematic of
the treatment paradigm for WT and Sirt1cKO mice with the 5-HT2A receptor agonist DOI (2 mg/kg) or vehicle. (P–T) Quantitation of mtDNA levels (P), mRNA
expression of Ppargc1a (Q), Tfam (R), and Cycs (S), and ATP levels (T) in WT and Sirt1cKO mice treated with DOI are expressed as fold change of WT+Veh ±
SEM (n = 8–12 animals per group). *P < 0.05 (compared with WT, two-way ANOVA, Tukey’s post hoc test).
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receptor. Stimulation of the 5-HT2A receptor recruits the
SIRT1–PGC-1α axis through PLC and MAPK signaling path-
ways, which enhance transcription of key factors such as
NRF1 and TFAM that drive mitochondrial biogenesis. We show
that SIRT1 is essential for the mitochondrial effects of 5-HT on
cortical neurons. Furthermore, 5-HT enhances mitochondrial
respiratory capacity, OXPHOS efficiency, and ATP production,
an effect also recapitulated through 5-HT2A receptor stimula-
tion. In agreement with our in vitro data, 5-HT2A receptor
stimulation, direct 5-HT infusion into the neocortex, and che-
mogenetic activation of Pet1–Cre-immunopositive serotonergic
neurons in hM3Dq/Pet1–Cre mice in vivo enhanced mitochon-
drial biogenesis, expression of several mitochondrial regulators,
and ATP levels within the neocortex. The in vivo effects of 5-HT2A
receptor stimulation on mitochondrial biogenesis and function were
mediated via SIRT1. Our in vivo studies demonstrated increased
state-2 and -3 respiration, indicative of enhanced mitochondrial ca-
pacity and OXPHOS efficiency, that contributed to an elevated ATP
production rate in response to 5-HT2A receptor stimulation. Pre-
exposure to 5-HT enhanced the ability of cortical neurons to buffer
excitotoxic and oxidative stress, accompanied by a reduction in cel-
lular ROS. SIRT1 was required for these prosurvival effects of 5-HT
and 5-HT2A receptor stimulation, suggesting the intriguing possibility
that the mitochondrial effects of 5-HT may underlie the enhanced
stress adaptation noted in cortical neurons. Our findings indicate
that 5-HT, through the 5-HT2A receptor, is an important upstream
factor that regulates neuronal mitochondrial biogenesis and function
via SIRT1 (Fig. 6). Furthermore, we highlight a robust prosurvival
effect of 5-HT and DOI on cortical neurons when challenged with
excitotoxic and oxidative insults, an effect mediated via SIRT1.
Prior reports indicated that specific 5-HT receptors can in-
fluence mitochondrial biogenesis in nonneuronal cells, such as
renal proximal tubular cells and cardiomyocytes. In renal prox-
imal tubular cells, 5-HT1F and 5-HT2A receptor activation pro-
motes mitochondrial biogenesis through PGC-1α and enhances
recovery following kidney injury (13, 14). In cardiomyocytes, 5-
HT promotes cell survival via the 5-HT2B receptor and PI3K–
Akt and MAPK pathways (15). Perinatal selective serotonin
reuptake inhibitor exposure is linked to increased mitochondrial
respiratory capacity and reduced ROS levels in cardiac tissue
(16) and liver (17), as well as sex-specific effects on brainstem
mitochondrial function (18). Thus far, few studies have examined
the direct influence of 5-HT on mitochondria in neurons.
Mitochondrial transport in hippocampal neurons, is promoted by
5-HT via the 5-HT1A receptor (9). A recent study demonstrated
that 5-HT1F receptor stimulation regulates mitochondrial bio-
genesis in nigral dopaminergic neurons and exerts neuro-
protective effects in an animal model of Parkinson’s disease (10).
Our findings highlight a key role of 5-HT via the 5-HT2A re-
ceptor, PLC and MAPK pathways, and the SIRT1–PGC-1α axis
in enhancing mitochondrial biogenesis and function both in
cortical neurons in vitro and in the neocortex in vivo. While our
results support a direct action of 5-HT/5-HT2A receptor stimu-
lation on mitochondrial biogenesis and function in the neo-
cortex, we cannot preclude the possibility of a role for indirect
mechanisms exerted via peripheral actions of 5-HT. Collectively,
these results highlight a putative prenervous trophic factor-like
action of 5-HT on mitochondria and suggest the possibility that
tissue-specific mitochondrial effects of 5-HT may involve distinct
5-HT receptors that facilitate cell survival and stress adaptation.
Interestingly, we did not observe any effect of NE and DA on
mitochondrial biogenesis or ATP levels in cortical neurons. DA
receptors have been linked to modulation of mitochondrial
respiration in the nucleus accumbens (19) and to inhibition of
mitochondrial motility in hippocampal neurons (20), suggesting
that other monoamines could exert circuit-specific influences on
mitochondria. In this vein, melatonin and N-acetylserotonin, a
precursor for melatonin, both exhibit neuroprotective effects,
hypothesized to involve inhibition of mitochondrial death pathways
(21, 22). While these reports suggest that diverse monoamines
could impinge on mitochondrial mechanisms as a component of
their neuroprotective action, they do not address whether mono-
amines directly target neuronal mitochondrial biogenesis and bio-
energetics and the underlying mechanisms. The focus of our studies
Fig. 6. Schematic depicting the putative mechanism
for 5-HT effects on mitochondrial biogenesis and
function. The model depicts 5-HT binding to the 5-
HT2A receptor expressed by cortical neurons, which
evokes an activation of the PLC and MAPK signaling
pathways. This recruitment of PLC and MAPK signal-
ing, likely through a multiple-step process, results in
recruitment of SIRT1, which is a key regulator of mi-
tochondrial biogenesis. SIRT1 may thenmodulate PGC-
1α expression, which has been shown to be a master
regulator of mitochondrial biogenesis and, in turn,
could enhance NRF1 and mitochondrial transcription
factor TFAM expression, thus mediating effects of 5-HT
on mitochondrial biogenesis. Our results indicate that
SIRT1 is required for the effects of both 5-HT and 5-
HT2A receptor agonists on mitochondrial biogenesis. In
addition, 5-HT and 5-HT2A receptor stimulation leads
to an increase in basal OCR, which may reflect a
heightened energetic demand that could, in turn,
drive a transcriptional program, leading to a sub-
sequent adaptive increase in mitochondrial content
and function. Furthermore, 5-HT and 5-HT2A receptor
agonists also enhance ATP production and increase
OXPHOS, maximal respiration, and spare respiratory
capacity. In addition, 5-HT also reduces cellular ROS
levels and enhances expression of antioxidant enzymes
in cortical neurons. This enhancement in mitochondrial
biogenesis and function may contribute to the effects
of 5-HT and 5-HT2A receptor agonists in conferring
neuronal protection from excitotoxic and oxidative
stress.
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has been to address the impact of 5-HT on mitochondrial biogenesis
and function; however, it is important to highlight that mitochondria
are highly dynamic organelles that constantly undergo fission and
fusion. We have not assessed effects of 5-HT on mitochondrial
morphology and dynamics, which merit future investigation. Our
in vivo studies were performed in adult animals, indicating that
the mitochondrial effects of 5-HT are reflective of actions in the
mature nervous system. Our results motivate future studies to
assess the mitochondrial effects of 5-HT during developmental
time windows.
The dose-dependent effects of 5-HT on mitochondrial bio-
genesis and bioenergetics were observed in the micromolar
concentration range. The neurotransmitter 5-HT has both syn-
aptic and extrasynaptic effects, and while synaptic vesicular
concentrations are estimated as high as 6 mM, 5-HT can
diffuse >20 μm away to extrasynaptic sites, where concentrations
fall into the micromolar and nanomolar range (23, 24). The
doses of 5-HT used in our study fall within this physiologically
relevant range (23, 25–27). Furthermore, DREADD-mediated
chemogenetic activation of Pet1-positive serotonergic neurons
in vivo also resulted in enhanced mitochondrial mass and func-
tion. Pharmacological and genetic loss-of-function studies clearly
demonstrate that the effects of 5-HT on mtDNA content,
Ppargc1a and Sirt1 expression, and ATP levels are mediated via
the 5-HT2A receptor. Strikingly, while these effects of 5-HT are
completely blocked by both pharmacological blockade or genetic
loss of the 5-HT2A receptor, we did not observe a basal change in
these measures. The absence of baseline mitochondrial changes
suggests functional redundancy in the pathways that modulate
neuronal mitochondrial biogenesis and function. The effects of
5-HT on mtDNA, gene expression, ATP levels, and OXPHOS
were phenocopied by 5-HT2A receptor stimulation of cortical
neurons and involved the PLC and MAPK, but not the PI3K–
Akt, signaling pathways (Fig. 6). However, we do not preclude
a role for additional signaling pathways that could be activated
by the 5-HT2A receptor, as we restricted our analysis to only the
major signaling cascades reported to lie downstream of 5-HT2A
receptor stimulation (28).
It is noteworthy that both hallucinogenic (DOI) and non-
hallucinogenic (Lisuride) ligands of the 5-HT2A receptor (29)
can enhance mitochondrial biogenesis and ATP levels, suggest-
ing a central role for the 5-HT2A receptor in neuronal bioener-
getics. Prior reports indicated that 5-HT2A receptor stimulation
enhances neurite outgrowth in cortical neurons (30) and is up-
stream of the regulation of trophic factors, such as BDNF (31).
BDNF has been shown to enhance mitochondrial docking at
synapses and regulate neuronal mitochondrial biogenesis via
PGC-1α (32, 33). This motivates future experiments to examine
the possibility of a coordinated interplay between 5-HT, the 5-
HT2A receptor, and BDNF in regulation of trophic and neuro-
protective effects, driven via an influence on mitochondria.
The influence of 5-HT on mitochondria in cortical neurons is
exerted by a transcriptional cascade involving master regulators
of mitochondrial biogenesis (SIRT1 and PGC-1α), whose ex-
pression is rapidly induced by 2–6 h, both in vitro and in vivo.
This is followed by a return to baseline and a second phase of
transcriptional activation at 48 h after sustained 5-HT/5-HT2A
receptor stimulation, which precedes the effects on enhanced
mitochondrial mass and function. This demonstrates that 5-HT
exerts transcriptional control of the SIRT1–PGC-1α axis and
indicates that priming of this axis may serve as the driver of the
mitochondrial effects of 5-HT. Furthermore, pharmacological
and genetic studies indicated that the effects of 5-HT on Sirt1
and Ppargc1a expression are mediated through the 5-HT2A re-
ceptor. In this context, it is relevant to consider the possibility that
the initiation of this transcriptional program by 5-HT/5-HT2A re-
ceptor stimulation could arise due to a heightened energetic de-
mand, reflected by increased basal mitochondrial respiration,
serving as the precursor event that contributes to a subsequent
adaptive increase in mitochondrial content and function (Fig. 6).
The SIRT1–PGC-1α axis activates a coordinated transcrip-
tional program to meet cellular energy demands, via modulation
of mitochondrial biogenesis and functions (6, 7). SIRT1-mediated
deacetylation activates PGC-1α, a master regulator of expression of
mitochondrial genes via NRF1 and TFAM (6, 8). NRF1 enhances
expression of OXPHOS machinery and promotes TFAM expres-
sion, which drives transcription and replication of mtDNA (6, 7).
Our results underscore the importance of SIRT1 for the effects of
5-HT and DOI on mitochondrial biogenesis and ATP levels.
Pharmacological blockade or genetic ablation of SIRT1 in cortical
neurons abrogated the effects of 5-HT on mitochondrial mass and
cellular ATP levels. Furthermore, our in vivo studies indicated that
the effects of DOI on gene expression, mitochondrial content, and
ATP levels in the neocortex were absent in Sirt1cKO mice. How-
ever, SIRT1 perturbations did not result in any baseline changes,
consistent with previous reports on SIRT1 loss of function and
mitochondrial output (34, 35). This suggests that baseline regula-
tion of mitochondrial biogenesis is likely modulated by multiple
pathways. Interestingly, studies with genetic loss of PGC-1α are also
similarly suggestive of functional redundancy, given they do not
show major baseline defects in mitochondrial biogenesis and
function (36). While our results do not allow us to conclude
whether PGC-1α is essential for the effects of 5-HT/5-HT2A re-
ceptor stimulation, given that both SIRT1 and PGC-1α are estab-
lished regulators of mitochondrial biogenesis/function (6, 8), our
findings suggest that the 5-HT–mediated SIRT1-dependent mito-
chondrial effects likely involve a role for PGC-1α. Together, our
results clearly illustrate that 5-HT or 5-HT2A receptor stimulation-
dependent induction of mitochondrial biogenesis and functions
requires SIRT1 in the cortical neurons.
In the context of neurons, the upstream factors that integrate
environmental cues and then impinge on the SIRT1–PGC-1α
axis to initiate mitochondrial biogenesis and facilitate adapta-
tion in response to altered energetic demands remain elusive.
Our findings demonstrate a hitherto-unidentified relationship
between 5-HT and SIRT1, providing evidence that 5-HT is an
upstream regulator of SIRT1. A previous study indicated that
SIRT1 can modulate serotonergic neurotransmission via tran-
scriptional effects on monoamine oxidase A expression (37), and
our findings raise the tantalizing possibility of a reciprocal re-
lationship between 5-HT and SIRT1 in the brain. Given the role
of 5-HT in facilitating stress adaptation, this suggests the possi-
bility that 5-HT could serve as a vital intermediary in enhancing
stress adaptation of neurons through recruitment of the SIRT1–
PGC-1α axis to enhance mitochondrial biogenesis and function,
thus endowing neurons with enhanced capacity to buffer stress.
Strikingly, 5-HT resulted in a robust reduction in cellular ROS
levels and significantly attenuated the enhanced ROS in cortical
neurons subjected to excitotoxic and oxidative stress. The con-
comitant increases evoked by 5-HT in the ROS-scavenging en-
zymes Sod2 and Cat suggest a role for these antioxidant enzymes
in the effects of 5-HT on ROS. Furthermore, 5-HT/5-HT2A re-
ceptor stimulation enhanced cortical neuron viability across a
wide range of doses for kainate and H2O2, a neuroprotective
effect that required SIRT1. Neurons face unique energetic de-
mands, and the ability of mitochondria to effectively respond to
alterations of environment and buffer the “allostatic” load of stress
defines the trajectory for neuronal survival (38). In this context, the
robust effects of 5-HT/5-HT2A receptor stimulation on spare re-
spiratory capacity may contribute to the improved neuronal survival
observed in neurons challenged with stress. Spare respiratory
capacity, through the ability to increase mitochondrial respiration
when challenged with enhanced energy demands, equips cells with
the ability to buffer extreme stress and serves as a critical factor
determining neuronal survival (39). These are significant findings,
given the emerging link between mitochondrial dysfunction and
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mood disorders, in particular a decline in ATP levels, increased
oxidative stress, and cortical apoptotic cell loss (40). Specifically,
our findings motivate future investigation to address the relation-
ship between the mitochondrial and behavioral effects of 5-HT,
both in the context of the pathogenesis and treatment of mood
disorders. There remains a limited understanding of potential drug
targets to induce mitochondrial biogenesis/function (41–43), and
our work supports the notion that the 5-HT2A receptor may serve
as a putative drug target to regulate mitochondrial physiology.
In conclusion, our findings demonstrate that 5-HT can in-
crease mitochondrial biogenesis and function in cortical neurons,
via a 5-HT2A receptor-dependent recruitment of the SIRT1–
PGC-1α axis. Through the 5-HT2A receptor, 5-HT exerts ro-
bust neuroprotective effects on cortical neurons buffering against
neurotoxic insults. SIRT1 lies downstream of 5-HT, through the
5-HT2A receptor in cortical neurons, and is essential for the ef-
fects of 5-HT on mitochondrial biogenesis, expression of regu-
lators of mitochondrial biogenesis, ATP levels, and enhanced
cell viability under stress. These mitochondrial effects of 5-HT
bear significance, in relation to the influence of 5-HT, in pro-
moting cell survival, neuronal plasticity, stress adaptation, and
regulation of senescence/aging.
Materials and Methods
SI Appendix contains a detailed description of materials and methods.
To establish in vitro primary cortical cultures, cortices were dissected from
E18.5 rat or mutant mouse embryos and were cultured as described in SI
Appendix, SI Materials and Methods. For in vivo experiments, male Sprague–
Dawley rats (5–6 mo), WT and Sirt1cKO mice (15 mo), bigenic hM3Dq/Pet1–
Cre mice (15 mo), and C57BL/6NCrl/Cri mice (5–6 mo) were used. Intracortical
infusion of 5-HT was carried out via delivery through osmotic minipumps
(Alzet 2001) implanted surgically in Sprague–Dawley rats. Experimental
procedures were performed in accordance with the guidelines of the Com-
mittee for Supervision and Care of Experimental Animals, Government of
India, and were approved by the Tata Institute of Fundamental Research
(TIFR) Institutional Animal Ethics Committee (CPCSEA-56/1999).
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